27.40

4.69% -1.61

Jyong Biotech Ltd (MENS)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$29.01

Offen:

$28.43

24-Stunden-Volumen:

30,640

Relative Volume:

0.09

Marktkapitalisierung:

$2.08B

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

-5.70%

1M Leistung:

-28.87%

6M Leistung:

+0.00%

1J Leistung:

+0.00%

1-Tages-Spanne:

$27.40

$28.98

1-Wochen-Bereich:

$26.22

$30.45

52-Wochen-Spanne:

$9.95

$67.00

Jyong Biotech Ltd Stock (MENS) Company Profile

Firmenname

Jyong Biotech Ltd

Sektor

Healthcare (1139)

Branche

Biotechnology (634)

Telefon

Adresse

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

MENS's Discussions on Twitter

Vergleichen Sie MENS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MENS Jyong Biotech Ltd	27.40	2.21B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	438.54	112.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	699.82	73.91B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	417.91	56.81B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	891.83	55.46B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	193.92	41.92B	447.02M	-1.18B	-906.14M	-6.1812

Jyong Biotech Ltd Aktie (MENS) Neueste Nachrichten

Dec 08, 2025

Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - Defense World

Dec 08, 2025

Dec 07, 2025

Jyong Biotech (NASDAQ:MENS) Shares Gap Down – Here’s Why - Defense World

Dec 07, 2025

Dec 06, 2025

Taiwan's Jyong Biotech expands regional partnership with MoU signing in Vietnam - BioSpectrum Asia

Dec 06, 2025

Dec 05, 2025

Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3%Time to Sell? - MarketBeat

Dec 05, 2025

Dec 04, 2025

Jyong Biotech expands regional partnerships, signs MoU with a Vietnam pharmaceutical distributor - marketscreener.com

Dec 04, 2025

Jyong Biotech Expands Regional Partnerships, Signs MoU With A Vietnam Pharmaceutical Distributor - TradingView

Dec 04, 2025

Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha

Nov 27, 2025

Nov 26, 2025

Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat

Nov 26, 2025

Taiwan's Jyong Biotech announces partnership in Korea to evaluate in‑licensing of plant-derived MCS drugs - BioSpectrum Asia

Nov 26, 2025

Nov 25, 2025

Jyong Biotech signs letter of intent with South Korean pharma company - Investing.com Australia

Nov 25, 2025

Nov 24, 2025

Jyong Biotech to Evaluate Licensing Deal for MCS-2 Drug Candidate in South Korea - marketscreener.com

Nov 24, 2025

Jyong Biotech signs letter of intent with South Korean pharma company By Investing.com - Investing.com South Africa

Nov 24, 2025

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs - The Manila Times

Nov 24, 2025

Jyong Biotech (Nasdaq: MENS) LOI to Evaluate MCS-2 Licensing with Korean Pharma - Stock Titan

Nov 24, 2025

Nov 21, 2025

Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat

Nov 21, 2025

Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance

Nov 21, 2025

Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance

Nov 21, 2025

Nov 20, 2025

Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria

Nov 20, 2025

Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com Nigeria

Nov 20, 2025

Jyong Biotech stock soars after positive Phase II prostate cancer drug results By Investing.com - Investing.com South Africa

Nov 20, 2025

Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - marketscreener.com

Nov 20, 2025

Jyong Biotech announces completion of primary endpoint statistical analysis for phase II clinical trial of MCS-8 with positive outcomes - MarketScreener

Nov 20, 2025

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes - The Manila Times

Nov 20, 2025

Jyong Biotech Announces Completion of Primary Endpoint - GlobeNewswire

Nov 20, 2025

Jyong Biotech reports positive results for prostate cancer drug in phase II trial By Investing.com - Investing.com South Africa

Nov 20, 2025

Nov 19, 2025

Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat

Nov 19, 2025